• Purpose : Evaluate the pharmacokinetic properties and safety of KD5001 and Exforge Tab./Crestor Tab. administration in healthy adult volunteers after oral administration.
• Target disease : Hypertension/Dyslipidemia
• Evaluation items :
 1) Pharmacokinetic assessment : AUClast, Cmax, AUCinf, Tmax, t1/2
 2) Safety assessment : Vital signs. 12-lead electrocardiogram, Clinical Laboratory Testing, Physical examination, Adverse Event Monitoring, Confirmation of medication use

Others

(Pharmacokinetic characteristics and safety evaluation)

• Target number of subjects : 48 subjects
• Study design : 2x4 Cross-over
• Test group : KD5001 1 tablet, Exforge/Crestor 1 tablet
• Reference group : KD5001 1 tablet, Exforge/Crestor 1 tablet

Arm Label

Target Number of Participant

Arm Type

Arm Description

1 Period : Exforge/Crestor  1 tablet, 2 Period : KD5001 1 tablet

Arm Label

Target Number of Participant

Arm Type

Arm Description

1 Period : KD5001  1 tablet, 2 Period : Exforge/Crestor 1 tablet

Gender

Age

Description

1) 스크리닝 검사 당시 연령이 만 19세 이상 건강한 성인
2) Those who have a body mass index (BMI) of 18.5 kg / m2 to 27.0 kg / m2 at screening
3) Patients with no congenital or chronic disease and no medically symptomatic findings
4) Those who have been determined to be eligible as a result of clinical tests and electrocardiogram tests, such as serum tests, hematology tests, blood chemistry tests, and urine tests, which were performed by the doctor in charge within 4 weeks prior to administration of the clinical trial drug
5) After fully hearing and understanding the details of this clinical trial, you agree to voluntarily decide to participate and to comply with the Notice

1) Persons who have a history of hypersensitivity reactions or other clinically significant hypersensitivity to other drugs or additives in the main components or components of clinical trial medicines
2) Persons with a history of drug absorption, distribution, metabolism, and excretion
3) Patients with hereditary angioedema or with a history of angioedema when treated with ACE inhibitors or angiotensin II receptor antagonists
4) Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
5) If there is a history or family history of genetic myopathy
6) 다른 HMG-CoA 환원효소 저해제 또는 피브레이트에 대한 근육 독성의 병력이 있는 경우
7) In patients with vital signs, the left systolic blood pressure ≥ 140 mmHg or <115 mmHg, the left ventricular diastolic blood pressure ≥ 90 mmHg or <70 mmHg
8) 활동성 간질환 환자 또는 AST, ALT, total bilirubin이 정상 범위 상한치의 1.5배를 초과하는 자
9) Creatinine clearance <80 mL / min (creatinine clearance is calculated by Cockcroft-Gault formula using serum creatinine)
10) Patients who have gastrointestinal diseases (Crohn's disease, active peptic ulcer, etc.) that may affect the absorption of clinical trial medications or gastrointestinal surgery (except for simple cecal surgery or hernia surgery)
11) Any person who has suffered a major injury within 4 weeks prior to the first dose, or who has undergone surgical procedures and who has suspected acute illness (severe infectious disease, severe trauma, severe diarrhea, vomiting, etc.)
12) (Cigarettes> 10 cfu / day) who are unable to abstain during the clinical trial from 3 days prior to the clinical trial, or those who are unable to continue drinking during the trial (21units / week, 1unit = 10g = 12.5mL of pure alcohol)
13) From the screening date until 30 days after the last clinical trial drug administration, appropriate double-pregnancy or medically acceptable contraceptive methods (including intrauterine devices with proven pregnancy failure rates, physical contraceptive methods and spermicide) Use, vasectomy, tubal resection / ligation, hysterectomy, etc.)
14) Women who are pregnant or who may be pregnant and breastfeeding
15) Any person taking any OTC medicines or herbal medicines within 2 weeks of the first day of medication or who has taken any OTC medication within 1 week will be subject to the judgment of the examiner that the medication will affect the test or the safety of the subject When it is judged to be influential
16) Those who have participated in other clinical studies within 6 months before the first administration day
17) Those who donated whole blood within 2 months before the first administration day, or those who donated blood within 1 month
18) Those who have had abnormal diets that can affect the absorption, distribution, metabolism and excretion of the drug (eg, take 1 mg or more of the grapefruit juice daily within 7 days prior to administration of the clinical trial drug)
19) Serum test (HBsAg, HCV Ab, HIV Ag / Ab, VDRL) Result positive
20) Those who are judged to be ineligible for participation in clinical trials at the discretion of the examiner and the examiner (doctor in charge)

From 0 h to the last quantifiable concentration Area under the concentration-time curve, peak serum concentration

Pre-dose(0h), 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48, 72h, 96hr

The area under the concentration-time curve from time 0 to infinity, Cmax arrival time

Pre-dose(0h), 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48, 72h, 96hr

AUCinf, Tmax, t1/2, CL/F

Pre-dose(0h), 0.5, 1, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 10, 12, 24, 48, 72h, 96hr